Simvastatin and pravastatin equally improve flow-mediated dilation in males with hypercholesterolemia

Wiener Klinische Wochenschrift

Volumn 114, Issue 23-24, 2002, Pages 999-1003

  Šebeštjen, Miran ^a   Boh, Marko ^b   Keber, Irena ^a  

^a UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^b KRKA D D   (Slovenia)

Author keywords

Endothelium; Hypercholesterolemia; Pravastatin; Simvastatin

Indexed keywords

CHOLESTEROL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ADULT; ARTERY BLOOD FLOW; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; BRACHIAL ARTERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; ECHOGRAPHY; HEMODYNAMICS; HUMAN; HYPERCHOLESTEROLEMIA; MALE; RANDOMIZED CONTROLLED TRIAL;

ANTICHOLESTEREMIC AGENTS; BRACHIAL ARTERY; CHOLESTEROL; CHOLESTEROL, HDL; ENDOTHELIUM, VASCULAR; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; PRAVASTATIN; SIMVASTATIN; TIME FACTORS; TREATMENT OUTCOME; TRIGLYCERIDES; VASODILATION;

EID: 12244309095     PISSN: 00435325     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Scandinavian Simvastatin Survival Study Group (1994) Randomized trail of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389
2. Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, Macfarlane PW, et al (1995) Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333: 1301-1307
3. Brown BC, Zhao XQ, Sacco DE, Albers JJ (1993) Lipid-lowering and plaque regression: new insight into prevention of plaque disruption and clinical events in coronary artery disease. Circulation 87: 1781-1791
4. Celermajer DS (1997) Endothelial dysfunction: does it matter? Is it reversible? J Am Coll Cardiol 30: 325-333
5. Egashira K, Hirooka Y, Kai H, Sugimachi M, Suzuki S, Inou T, et al (1994) Reduction in serum cholesterol with pravastatin improves endothelium-dependent coronary vasomotion in patients with hypercholesterolemia. Circulation 89: 2519-2524
6. O'Driscoll G, Green D, Taylor RR (1997) Simvastatin, an HMG-coenzyme A reductase inhibitor improves endothelial function within 1 month. Circulation 95: 1126-1131
7. Ludmer PI, Selwyn AP, Shook TL, Wayne RR, Mudge GH Alexander RW, et al (1986) Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 315: 1046-1051
8. Chowienczyk PJ, Watts GF, Cockcroft JR, Ritter JM (1992) Impaired endothelium-dependent vasodilatation of forearm resistance vessels in hypercholesterolemia. Lancet 340:1430-1432
9. Steinberg HO, Bayazeed B, Hook G, Johnson A, Cronin J, Baron AD (1997) Endothelial dysfunction is associated with cholesterol levels in the hihg normal range in humans. Circulation 96: 3287-3293
10. Laufs U, La Fata V, Plutzky J, Liao JK (1998) Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation 97: 1129-1135
11. Kaesemeyer WH, Caldwell RB, Huang J, Caldwell RW (1999) Pravastatin sodium activates endothelial nitric oxide synthase independent of its cholesterol-lowering actions. J Am Coll Cardiol 33: 234-241
12. Friedwald WT, Levy RI, Frederickson DS (1972) Estimation of the concentration of low density lipoprotein cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 18: 499-502
13. Celermajer DS, Sorensen KE, Gooch VM, Spiegelhalter DJ, Miller OI, Sullivan ID, et al (1992) Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 340: 1111-1115
14. Vita JA, Yeung AC, Winniford M, Hodgson JM, Treasure CB, Klein JL, et al (2000) Effect of cholesterol-lowering therapy on coronary endothelial vasomotor function in patients with coronary artery disease. Circulation 102: 846-851
15. Neunteufl T, Kostner K, Katzenschlager R, Zehetgruber M, Maurer G, Weidinger F (1998) Additional benefit of vitamin E supplementation to simvastatin therapy on vasoreactivity of the brachial artery of hypercholesterolemic men. J Am Coll Cardiol 32: 711-716
16. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, et al (1995) Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 332: 481-487
17. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P (1995) The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 332: 488-493
18. Tamai O, Matsuoka H, Itabe H, Wada Y, Kohno K, Imaizumi T (1997) Single LDL apheresis improves endothelium-dependent vasodilatation in hypercholesterolemic humans. Circulation 95: 76-82
19. Chauhan A, Mullins PA, Taylor G, Petch MC, Schofield PM (1997) Both endothelium-dependent and endothelium-independent function is impaired in patients with angina pectoris and normal coronary angiograms. Eur Heart J 18: 60-68
20. Šebeštjen M, Žegura B, Keber I (2002) Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidemia. J Intern Med 251: 77-85
21. Schachinger V, Britten MB, Zeiher AM (2000) Prognostic impact of coronary vasodilator dysfunction on adverse long-term outcome of coronary heart disease. Circulation 101: 1899-1906
22. Anderson TJ, Uehata A, Gerhard MD, Meredith IT, Knab S, Delagrange D, et al (1995) Close relation of endothelial function in the human coronary and peripheral circulations. J Am Coll Cardiol 26: 1235-1241